Programme
-
**Note: timings are in CET**
-
Moderator: Dave Dillon, Senior Regulatory and Compliance Analyst, Chemical Watch, UK
- Session 1: Overviews
-
Welcome and introduction
-
EU Commission overview
-
Echa overview
-
Challenges and opportunities of the BPR from an industry perspective
- Progress and feedback
- Impact of changing guidance and norms on biocidal actives and products
- Review programme and innovations
-
Q&A and panel discussion
-
Networking and break
- Session 2: The assessment of endocrine disrupting chemicals under the BPR
-
Introduction
-
ED assessment of biocides: experiences so far
- The ED assessment in the BPR process
- The role of the ED expert group
- Experiences so far and outlook
-
Endocrine Guideline Optimisation (ERGO): Breaking down the wall between human health and environmental testing of endocrine disruptors
Objectives are:
- To improve identification and hazard assessment of EDCs
- to break down the wall between different research fields that investigate adverse effects of EDCs in different vertebrate classes
- To demonstrate feasibility of extrapolating effects of EDCs from non-mammalian to mammalian vertebrates
Henrik Holbech
Associate Professor, Department of Biology, University of Southern Denmark, Department of Biology -
Endocrine disruptor screening assessment of co-formulants in biocidal products: First experiences and development of an IT tool
- First experiences with ED assessments
- Development and use of EDScreener
- Other (regulatory) developments
- Conclusions and future outlook
-
Q&A and panel discussion
-
Break and sponsor workshop
Moderator: Henry Tipping, Publishing Manager, Chemical Watch
Environmental Risk Assessment challenges under the BPR, with a focus on PT2 and PT21
The wide spectrum of product types covered by the BPR means that the approach to environmental risk assessment must be modified in each case. There are general principles that can be applied for environmental risk assessments; however, the use patterns and treatment of environmental inputs must be tailored to each product type submission. This presentation will cover these basic approaches and focus on some of the specific adaptations necessary.
- Session 3: Efficacy updates
-
Introduction
-
Scope issues and guidance for PT11 and PT12 (only paper industry) efficacy
- Background of the guidance
- Structure of the guidance
- Critical points
- Next steps: PT12 guidance for oilfield area
-
Emerging CEN methods and updates to ECHA EFF guidance
- CEN basics
- CEN working groups and norm structure
- Upcoming CEN method developments
- Interface of CEN norms and ECHA BPR EFF guidance
- Structure of BPR EFF guidance
- Updates to ECHA EFF guidance:
- TAB updates
- Appendix 4 updates
-
Q&A and panel discussion
including additional panellists
-
Take home messages
-
End of day one
